|
1
|
Siegel R, Desantis C and Jemal A:
Colorectal cancer statistics, 2014. CA Cancer J Clin. 64:104–117.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
DaVee T, Ajani JA and Lee JH: Is
endoscopic ultrasound examination necessary in the management of
esophageal cancer? World J Gastroenterol. 23:751–762. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cooper JS, Guo MD, Herskovic A, Macdonald
JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler
JJ, Spencer S, et al: Chemoradiotherapy of locally advanced
esophageal cancer: Long-term follow-up of a prospective randomized
trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA.
281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhao KL, Liu G, Jiang GL, Wang Y, Zhong
LJ, Wang Y, Yao WQ, Guo XM, Wu GD, Zhu LX and Shi XH: Association
of haemoglobin level with morbidity and mortality of patients with
locally advanced oesophageal carcinoma undergoing radiotherapy-a
secondary analysis of three consecutive clinical phase III trials.
Clin Oncol (R Coll Radiol). 18:621–627. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maouris PG and Hirsch PJ: Pregnancy in
women with thalidomide-induced disabilities. Case report and a
questionnaire study. Br J Obstet Gynaecol. 95:717–719. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zhou S, Wang F, Hsieh TC, Wu JM and Wu E:
Thalidomide-a notorious sedative to a wonder anticancer drug. Curr
Med Chem. 20:4102–4108. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Rades D, Golke H, Schild SE and Kilic E:
Impact of VEGF and VEGF receptor 1 (FLT1) expression on the
prognosis of stage III esophageal cancer patients after
radiochemotherapy. Strahlenther Onkol. 184:416–420. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Yoon MS, Nam TK, Lee JS, Cho SH, Song JY,
Ahn SJ, Chung IJ, Jeong JU, Chung WK and Nah BS: VEGF as a
predictor for response to definitive chemoradiotherapy and COX-2 as
a prognosticator for survival in esophageal squamous cell
carcinoma. J Korean Med Sci. 26:513–520. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yu J, Liu F, Sun M, Sun Z and Sun S:
Enhancement of radiosensitivity and the potential mechanism on
human esophageal carcinoma cells by tetrandrine. Cancer Biother
Radiopharm. 26:437–442. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu J, Liu F, Sun Z, Sun M and Sun S: The
enhancement of radiosensitivity in human esophageal carcinoma cells
by thalidomide and its potential mechanism. Cancer Biother
Radiopharm. 26:219–227. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang J, Yu JP, Wang JL, Ni XC, Sun ZQ, Sun
W, Nie B, Jiang JT, Sun SP and Wu CP: Pathologic response and
changes of serum VEGF during chemoradiotherapy may predict
prognosis in non-surgical patients with esophageal carcinoma.
Zhonghua Zhong Liu Za Zhi. 38:589–595. 2016.(In Chinese).
PubMed/NCBI
|
|
12
|
Yu JP, Sun SP, Sun ZQ, Ni XC, Wang J, Li
Y, Hu LJ and Li DQ: Clinical trial of thalidomide combined with
radiotherapy in patients with esophageal cancer. World J
Gastroenterol. 20:5098–5103. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Milstein JM, Cohen ME and Sinks LF: The
influence and reliability of neurologic assessment and Karnofsky
performance score on prognosis. Cancer 56 (7 Suppl). S1834–S1836.
1985. View Article : Google Scholar
|
|
14
|
Strong VE, D'Amico TA, Kleinberg L and
Ajani J: Impact of the 7th Edition AJCC staging classification on
the NCCN clinical practice guidelines in oncology for gastric and
esophageal cancers. J Natl Compr Canc Netw. 11:60–66. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Coche E: Recist and beyond. JBR-BTR.
96:167–171. 2013.PubMed/NCBI
|
|
16
|
Zhang TR, Zhao T, Xu X, Gu XW and Pan YK:
Efficacy and side-effects of docetaxel combined with cisplatin on
the treatment of local advanced esophageal cancer with concomitant
radiation therapy. Zhonghua Zhong Liu Za Zhi. 32:791–794. 2010.(In
Chinese). PubMed/NCBI
|
|
17
|
National Comprehensive Cancer Network, .
NCCN. 2016.[EB/OL]. https://www.nccn.org/August 20–2016
|
|
18
|
Crehange G, Maingon P, Peignaux K, N'guyen
TD, Mirabel X, Marchal C, Verrelle P, Roullet B, Bonnetain F and
Bedenne L; Federation Francophone de Cancerologie Digestive 9102, :
Phase III trial of protracted compared with split-course
chemoradiation for esophageal carcinoma: Federation francophone de
cancerologie digestive 9102. J Clin Oncol. 25:4895–4901. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu JP, Lu WB, Wang JL, Ni XC, Wang J, Sun
ZQ and Sun SP: Pathologic response during chemo-radiotherapy and
variation of serum VEGF levels could predict effects of
chemo-radiotherapy in patients with esophageal cancer. Asian Pac J
Cancer Prev. 16:1111–1116. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lu JJ, Ma J, Miao R, Gu Y and Zhong FT:
Expression of vascular endothelial growth factor D in human
esophageal squamous cell carcinoma tissue and its significance.
Zhonghua Wei Chang Wai Ke Za Zhi. 16:1191–1194. 2013.(In Chinese).
PubMed/NCBI
|
|
21
|
Bedoya F, Meneu JC, Macías MI, Moreno A,
Enríquez-De-Salamanca R, Gonzalez EM and Vegh I: Mutation in CNR1
gene and VEGF expression in esophageal cancer. Tumori. 95:68–75.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Srivastava VK, Gara RK, Rastogi N, Mishra
DP, Ahmed MK, Gupta S, Goel MM and Bhatt ML: Serum vascular
endothelial growth factor-A (VEGF-A) as a biomarker in squamous
cell carcinoma of head and neck patients undergoing
chemoradiotherapy. Asian Pac J Cancer Prev. 15:3261–3265. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singhal S, Mehta J, Desikan R, Ayers D,
Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar
M, et al: Antitumor activity of thalidomide in refractory multiple
myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Steins MB, Bieker R, Padró T, Kessler T,
Kienast J, Berdel WE and Mesters RM: Thalidomide for the treatment
of acute myeloid leukemia. Leuk Lymphoma. 44:1489–1493. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kay NE, Shanafelt TD, Call TG, Wu W and
Laplant BR: N9986: A phase II trial of thalidomide in patients with
relapsed chronic lymphocytic leukemia. Leuk Lymphoma. 50:588–592.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Townsend W, Johnson RJ, Pottinger BT,
Counsell N, Smith P, Chadwick H, Evans K, Wickham C and Rudin CE;
UK NCRI Lymphoma Clinical Studies Group, : A phase II clinical
trial of fludarabine and cyclophosphamide followed by thalidomide
for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial.
CRUK number C17050/A5320. Leuk Lymphoma. 57:2232–2234. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kumar S, Witzig TE and Rajkumar SV:
Thalidomid: Current role in the treatment of non-plasma cell
malignancies. J Clin Oncol. 22:2477–2488. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rehman W, Arfons LM and Lazarus HM: The
rise, fall and subsequent triumph of thalidomide: Lessons learned
in drug development. Ther Adv Hematol. 2:291–308. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sauer H, Günther J, Hescheler J and
Wartenberg M: Thalidomide inhibits angiogenesis in embryoid bodies
by the generation of hydroxyl radicals. Am J Pathol. 156:151–158.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goel S, Wong AH and Jain RK: Vascular
normalization as a therapeutic strategy for malignant and
nonmalignant disease. Cold Spring Harb Perspect Med. 2:a0064862012.
View Article : Google Scholar : PubMed/NCBI
|
